News
The GenCost 2024-25 report, published annually by CSIRO in partnership with the Australian Energy Market Operator (AEMO), has ...
The Phase 1 clinical trial recently initiated in China is a single-center, randomized, double-blind, placebo-controlled, dose-escalation study designed to evaluate the safety, tolerability, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback